Nieborowska-Skorska M, Maifrede S, Dasgupta Y, et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017;130(26):2848-2859. (PubMed, Blood) - Aug 28, 2026 - No abstract available
Journal • Myeloproliferative Neoplasm • Oncology
|